GSK Investigational Site

Shelby, North Carolina 28152

1 studies enrolling now · 23 studies all time

What they study most

Asthma, Diabetes Mellitus, Type 2, Pulmonary Disease, Chronic Obstructive

Studies at this site

• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) — Recruiting now
• A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease — Running, not enrolling
• Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level — Completed
• A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma — Completed
• Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus — Completed
• Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma — Completed
• A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus — Completed
• A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. — Completed
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old — Completed
• An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma. — Completed
• Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents — Completed
• A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD — Completed
• A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment. — Completed
• A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide. — Completed
• Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes — Completed
• Safety and Efficacy of Albiglutide in Type 2 Diabetes — Completed
• Safety and Efficacy Study of Albiglutide in Type 2 Diabetes — Completed
• A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes — Completed
• A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes — Completed
• Cross-sectional Study for Identification and Description of Severe Asthma Patients — Completed